| Autor: |
Wojda SJ; Department of Biomedical Engineering, University of Massachusetts Amherst, Amherst, Massachusetts, USA., Marozas IA; Department of Chemical and Biological Engineering and the BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA., Anseth KS; Department of Chemical and Biological Engineering and the BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA., Yaszemski MJ; Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA., Donahue SW; Department of Biomedical Engineering, University of Massachusetts Amherst, Amherst, Massachusetts, USA.; Department of Mechanical Engineering, Colorado State University, Fort Collins, Colorado, USA. |
| Abstrakt: |
Characterizing the release profile for materials-directed local delivery of bioactive molecules and its effect on bone regeneration is an important step to improve our understanding of, and ability to optimize, the bone healing response. This study examined the local delivery of parathyroid hormone (PTH) using a thiol-ene hydrogel embedded in a porous poly(propylene fumarate) (PPF) scaffold for bone regeneration applications. The aim of this study was to characterize the degradation-controlled in vitro release kinetics of PTH from the thiol-ene hydrogels, in vivo hydrogel degradation in a subcutaneous implant model, and bone healing in a rat critical size bone defect. Tethering PTH to the hydrogel matrix eliminated the early timepoint burst release that was observed in previous in vitro work where PTH was free to diffuse out of the matrix. Only 8% of the tethered PTH was released from the hydrogel during the first 2 weeks, but by day 21, 80% of the PTH was released, and complete release was achieved by day 28. In vivo implantation revealed that complete degradation of the hydrogel alone occurred by day 21; however, when incorporated in a three-dimensional printed osteoconductive PPF scaffold, the hydrogel persisted for >56 days. Treatment of bone defects with the composite thiol-ene hydrogel-PPF scaffold, delivering either 3 or 10 μg of tethered PTH 1-84, was found to increase bridging of critical size bone defects, whereas treatment with 30 μg of tethered PTH resulted in less bone ingrowth into the defect area. Continued development of this biomaterial delivery system for PTH could lead to improved therapies for treatment of nonunion fractures and critical size bone defects. |
